I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Belgium

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Metabolism EASD 2026
Roche and Genentech at

EASD 2026

September 28 - October 02
Milan, Italy / Virtual (Hybrid)
easd.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
08:00 AM
Duration 15mins Milan, Italy
Acmopatide (CT-868), a GLP-1/GIP Receptor Agonist, Reduced Body Weight with Proportionate Response in Fat and Lean Mass in People with Type 1 Diabetes in a 16-Week Phase 2 Trial
Klara Klein, J.Fredrickson, R.Pratley, B.D. Kayser, H.K. Akturk, N.LI, M.Kipnes, B.Ulmer. G.E. Sonnenberg
Metabolism - Cardiovascular | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:45 AM
Duration 60mins Milan, Italy
Enicepatide (CT-388), a GLP-1/GIP Receptor Agonist, Reduced CV Prognostic Markers of Central and Visceral Adiposity in Adults With Obesity/Overweight With ≥1 Weight-Related Comorbidity in a Phase 2 Trial
Helen Colhoun, Javed Butler, Ji (Emmy) Cheng, Julie Ishida, Macy Gipson, Nikolaus Marx, Odd Erik Johansen, Xuwei Hou
Metabolism - Cardiovascular | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Milan, Italy
Behavioral Insulin Timing: The Impact Of Nutrient Types And CGM Baselines On Bolus Omission And Delay
Ezgi Cinar, Michael Mitter, Amalia Ruiz Serrano, Cristian Galán Augé
Metabolism | Diabetes Mellitus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 4mins Milan, Italy
Enicepatide (CT-388), a GLP-1/GIP Receptor Agonist, Reduced CV Prognostic Markers of Central and Visceral Adiposity in Adults With Obesity/Overweight With ≥1 Weight-Related Comorbidity in a Phase 2 Trial
Helen Colhoun, Javed Butler, Ji (Emmy) Cheng, Julie Ishida, Macy Gipson, Nikolaus Marx, Odd Erik Johansen, Xuwei Hou
Metabolism - Cardiovascular | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 4mins Milan, Italy
Quantitative modeling suggests CT-868 reduces glucose appearance and improves insulin sensitivity, coinciding with modulation of glucagon dynamics in type 1 diabetes
Benjamin Ribba, Pau Herrero, Mattia Zanon, Brian Ulmer, Richard Pratley, Gabriele Sonnenberg, Damian Bialonczyk
Metabolism | Diabetes Mellitus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 AM
Duration 60mins Milan, Italy
Enicepatide (CT-388), a GLP-1/GIP Receptor Agonist, Reduced Cardiovascular Risk Factors in People With Overweight/Obesity in a Phase 2 Trial
Carel Le-Roux, Alexandra Steinberg, Dan Lender, Esther Shearer-Kang, Harold Bays, Ildiko Lingvay, Jeffrey Willis, Ji (Emmy) Cheng, Kenneth Kim, Odd Erik Johansen, Sureka Bollepalli
Metabolism - Cardiovascular | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Milan, Italy
Enicepatide (CT-388), a GLP-1/GIP Receptor Agonist, Reduced Vascular, Haemodynamic and Body Fluid Parameters in People With Overweight/Obesity in a Phase 2 Trial
Odd Erik Johansen, Diego Rebella, Javed Butler, Ji (Emmy) Cheng, Macy Gipson, Mark Petrie, Nikolaus Marx, Xuwei Hou
Metabolism - Cardiovascular | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Milan, Italy
Anaerobic Activity Shows The Largest 24-Hour Reduction In Glycaemic Variability In A Real-World CGM Analysis Of Over 160.000 Exercise Sessions In Type 2 Diabetes
Josip Zivkovic, Othmar Moser, Michael Mitter, Ajandek Peak, Johanna Kober
Metabolism | Diabetes Mellitus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 4mins Milan, Italy
Enicepatide (CT-388), a GLP-1/GIP Receptor Agonist, Reduced Cardiovascular Risk Factors in People With Overweight/Obesity in a Phase 2 Trial
Carel Le-Roux, Alexandra Steinberg, Dan Lender, Esther Shearer-Kang, Harold Bays, Ildiko Lingvay, Jeffrey Willis, Jennifer Green, Ji (Emmy) Cheng, Kenneth Kim, Odd Erik Johansen, Sureka Bollepalli
Metabolism - Cardiovascular | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 4mins Milan, Italy
Enicepatide (CT-388), a GLP-1/GIP Receptor Agonist, Reduced Vascular, Haemodynamic and Body Fluid Parameters in People With Overweight/Obesity in a Phase 2 Trial
Odd Erik Johansen, Diego Rebella, Javed Butler, Ji (Emmy) Cheng, Macy Gipson, Mark Petrie, Nikolaus Marx, Xuwei Hou
Metabolism - Cardiovascular | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:40 PM
Duration 60mins Milan, Italy
Petrelintide, a human amylin analog for the treatment of obesity: results from a phase 2, randomised, double-blind, placebo-controlled trial (ZUPREME 1)
W. Timothy Garvey, Jamy Ard, Lisa Connery, Juan Pablo Frias, Carel le Roux, Malene Dinesen, Berith Fredsted Hagen, Louise Larsen, Dan Hesse, Steven R. Smith
Metabolism | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:30 PM
Duration 10mins Milan, Italy
Enicepatide (CT-388), a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: Results From the 48-Weeks Phase 2 Study
Ildiko Lingvay, Alexandra Steinberg, Ania Jastreboff, Carel Le Roux, Dan Lender, Esther Shearer-Kang, Giuseppe Palermo, Harold Bays, Jeffrey Willis, Kenneth Kim, Manu Chakravarthy, Sureka Bollepalli
Metabolism - Cardiovascular | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:45 AM
Duration 60mins Milan, Italy
Safety and Pharmacodynamics of CT-996, an Oral Small-Molecule, cAMP Signal-Biased GLP-1 Receptor Agonist, Over 4 Weeks in Adults With Overweight/Obesity and Type 2 Diabetes
Manu Chakravarthy, Dietmar Volz, Federico A Argüelles-Tello, Leyla L Sanchez-Sanchez, Stacey Toussaint Touson
Metabolism - Cardiovascular | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Milan, Italy
Heterogeneous Post‐Exercise Hypo‐ And Hyperglycemia Patterns Reveal The Need For Individualized Support In People With Diabetes
Josip Zivkovic, Elisabeth Kneip, Ajandek Peak, Johanna Kober
Metabolism | Diabetes Mellitus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 4mins Milan, Italy
Safety and Pharmacodynamics of CT-996, an Oral Small-Molecule, cAMP Signal-Biased GLP-1 Receptor Agonist, Over 4 Weeks in Adults With Overweight/Obesity and Type 2 Diabetes
Manu Chakravarthy, Dietmar Volz, Federico A Argüelles-Tello, Leyla L Sanchez-Sanchez, Stacey Toussaint Touson
Metabolism - Cardiovascular | Obesity

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 60mins Milan, Italy
Over-Bolusing Before Exercise: A Cohort-Level Analysis Of Hypoglycemia Risk In People With Diabetes
Eemeli Leppäaho, Ajandek Peak, Johanna Kober
Metabolism | Diabetes Mellitus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Milan, Italy
Persistent Postprandial Hyperglycemia In Highly Engaged Digital Therapeutics Users: Identifying Gaps In Meal Management
Cristian Galán Augé, Michael Mitter, Amalia Ruiz Serrano, Ezgi Cinar
Metabolism | Diabetes Mellitus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.